185564-00-5

Basic information

• Product Name: L-Alanine, 3-[[[4,5-dihydro-5-[4-[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]butyl]- 3-isoxazolyl]carbonyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-
• CAS NO: 185564-00-5
• Molecular Formula: C42H46N6O6S
• Molecular Weight: 762.93
• Mol File: 185564-00-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: L-Alanine, 3-[[[4,5-dihydro-5-[4-[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]butyl]- 3-isoxazolyl]carbonyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Alanine, 3-[[[4,5-dihydro-5-[4-[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]butyl]- 3-isoxazolyl]carbonyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-(185564-00-5)
• EPA Substance Registry System: L-Alanine, 3-[[[4,5-dihydro-5-[4-[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]butyl]- 3-isoxazolyl]carbonyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-(185564-00-5)

Safety Data

• Hazardous Substances Data: 185564-00-5(Hazardous Substances Data)

Upstream product

• 185563-94-4 3-Ethoxycarbonyl-5-[4-(1-triphenylmethylimidazol-2-ylamino)butyl]isoxazoline 
• 185563-95-5 5-[4-(1-triphenylmethylimidazol-2-ylamino)butyl]isoxazoline-3-carboxylic acid 
• 185563-92-2 1Triphenylmethyl-2-phthalimidoimidazole 
• 185563-98-8 3S-3-amino-2-(2,4,6-trimethylbenzenesulfonylamino)propionic acid tert-butyl ester 
• 185563-96-6 N₂-(2,4,6-trimethylbenzenesulfonyl)-L-asparagine 
• 185563-97-7 3-amino-N-(2,4,6-trimethylphenyl)sulfonylamino-L-alanine 
• 185563-93-3 1-(triphenylmethyl)imidazole-2-ylamine 
• 185563-77-3 3-ethoxycarbonyl-5-(4-hydroxybutyl)isoxazoline 
• 185563-78-4 ethyl 5-(4-oxobutyl)isoxazoline-3-carboxylate 
• 821-41-0 5-Hexen-1-ol 
• 773-64-8 2-mesitylenesulphonyl chloride 
• 185563-99-9 2-(2,4,6-trimethyl-benzenesulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid tert-butyl ester 

Relevant articles and documents

Isoxazolines as potent antagonists of the integrin α(v)β3

Starting with lead compound 2, we sought to increase the selectivity for α(v)β3-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent α to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of α(v)β3. In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for α(v)β3-mediated adhesion versus α(IIb)β3-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the α- substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective α(v)β3 antagonist 3h was found to be a potent inhibitor of α(v)β3-mediated cell migration.